Results 1 to 10 of about 718,683 (284)
G-quadruplex homeostasis is a determinant of PARP inhibitor toxicity in BRCA2-deficient cells [PDF]
Nature CommunicationsInhibition of PARPs is a key strategy to treat tumours with defects in homologous recombination (HR), including those with mutations in the tumour suppressor gene BRCA2.
Abhishek Bharadwaj Sharma +8 more
doaj +2 more sources
Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study [PDF]
Frontiers in OncologyBackgroundPARP(Poly(ADP-ribose) polymerase) inhibitors are established as effective treatment for ovarian cancer; however, there have been no systematic studies of PARP inhibitor use in older patients with ovarian cancer.MethodsThis study was conducted ...
Jingjing Lu +6 more
doaj +2 more sources
Hereditary Cancer in Clinical Practice, 2015 بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b).
Maheen Anwar +2 more
+8 more sources
Annals of Internal Medicine: Clinical Cases, 2023 Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical ...
Xi Zhang +5 more
doaj +1 more source
PARP inhibitors: the race is on [PDF]
British Journal of Cancer, 2016 Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 (BRCA1/2) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition (Bryant et al, 2005; Farmer et al, 2005), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific ...
Brown, Jessica S +2 more
openaire +2 more sources
Scientific Reports, 2021 Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in EOC
Z. Ping Lin +9 more
doaj +1 more source
Redox Biology, 2021 Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant clinical benefits from PARP inhibitors, calling for the needs to further ...
Ting Hong +8 more
doaj +1 more source
A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
Signal Transduction and Targeted Therapy, 2023 Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency.
Chao Zhang +33 more
doaj +1 more source
99529 The Role of ATF6-Mediated Signaling in PARP Inhibitor Resistant Ovarian Cancer
Journal of Clinical and Translational Science, 2021 IMPACT: This work has the potential to identify targetable pathways conveying resistance to PARP inhibitors that may improve ovarian cancer patient outcomes. OBJECTIVES/GOALS: High grade serous ovarian cancer is the deadliest gynecologic malignancy. PARP
Alexandra, Benjamin Bitler
doaj +1 more source